Evidence map›Paper›PMID 36039152›Full record

ArticleIDCases2022

Disseminated histoplasmosis and hemophagocytic lymphohistiocytosis in a patient receiving TNF-alpha inhibitor therapy.

Qiaonan Zhong, Eloy E Ordaya, Santiago Delgado Fernandez, Kristin Lescalleet, Daniel Larson, Bobbi Pritt, Elie Berbari

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in IDCases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.0field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Qiaonan ZhongDepartment of Medicine, Mayo Clinic, Rochester, MN, USA.
Eloy E OrdayaDivision of Infectious Disease, Mayo Clinic, Rochester, MN, USA.
Santiago Delgado FernandezDivision of Clinic Microbiology, Mayo Clinic, Rochester, MN, USA.
Kristin LescalleetDepartment of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
Daniel LarsonDivision of Hematopathology, Mayo Clinic, Rochester, MN, USA.
Bobbi PrittDivision of Clinic Microbiology, Mayo Clinic, Rochester, MN, USA.
Elie BerbariDivision of Infectious Disease, Mayo Clinic, Rochester, MN, USA.
WinnMed · USMayo Clinic in Arizona · USMayo Clinic · USMayo Clinic in Florida · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Histoplasmosis commonly presents as an asymptomatic or self-limited infection in immunocompetent patients, but immunocompromised hosts may present with severe and disseminated disease. Herein, we present a 26-year-old male with history of ulcerative colitis receiving long-term TNF-alpha inhibitor therapy who presented with six months of diarrhea and recently fever and hematochezia. On admission, he was febrile and hypotensive, with initial workup revealing pancytopenia and imaging reporting pulmonary infiltrates, pancolitis, and enlarged mesenteric lymph nodes. Disseminated histoplasmosis was ultimately diagnosed after examination of the colonic biopsy. Bone marrow biopsy was also consistent with the diagnosis of histoplasmosis but also demonstrated hemophagocytic lymphohistiocytosis. The patient was ultimately treated with amphotericin B, intravenous immunoglobulin, etoposide, and corticosteroids.

Indexed as

Disseminated histoplasmosisHemophagocytic lymphohistiocytosisTNF-alpha inhibitorUlcerative colitis

Identifiers

PMID36039152
PMCPMC9418189
OpenAlexW4292342936

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.